This is a randomized, double-blind, placebo-controlled, parallel-group study to verify the clinical benefit of aducanumab (BIIB037) in participants with Alzheimer’s disease.
Basic eligibility criteria:
- Ages 60-85
- Amnestic MCI or early AD. MMSE>=22
- Cannot be on anticoagulation or have significant vascular disease on brain MRI
- No serious medical conditions that would limit study participation